Reference health
Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma
49/49 checkable references clean · checked 2026-07-23
Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.
1 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.
The 49 checked references that resolve
resolves10.1200/JCO.2005.05.0682
Treatment of Advanced Head and Neck Cancer: What Lessons Have We Learned?
resolves10.1056/NEJMoa053422
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
resolves10.1158/2159-8290.CD-12-0362
Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives
resolves10.1158/1078-0432.CCR-11-0699
Molecular Pathways: Fibroblast Growth Factor Signaling: A New Therapeutic Opportunity in Cancer
resolves10.1053/j.seminoncol.2015.09.027
Fibroblast Growth Factor (FGF) Receptor/FGF Inhibitors: Novel Targets and Strategies for Optimization of Response of Solid Tumors
resolves10.1158/2159-8290.CD-18-0229
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1–3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with
<i>FGFR3</i>
Alterations
resolves10.1158/1078-0432.CCR-18-1959
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring
<i>FGFR</i>
Gene Alterations
resolves10.1016/j.annonc.2020.06.018
Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors
resolves10.1038/bjc.2013.577
EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy
resolves10.1016/j.cell.2020.08.053
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer
resolves10.1007/s00262-021-02940-5
Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery
resolves10.1038/srep16280
Targeting HER-3 to elicit antitumor helper T cells against head and neck squamous cell carcinoma
resolves10.1007/s00262-008-0587-1
HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice
resolves10.1084/jem.20091918
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
resolves10.1002/pro.3987
The Human Protein Atlas—Spatial localization of the human proteome in health and disease
resolves10.1158/1078-0432.CCR-15-1874
FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma
resolves10.1111/his.13739
<scp>FGF</scp>‐2 and <scp>FGFR</scp>‐1 might be independent prognostic factors in oral tongue squamous cell carcinoma
resolves10.1016/j.ejca.2017.12.016
Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival
resolves10.1158/1078-0432.CCR-13-3310
Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas
resolves10.1158/0008-5472.CAN-07-2615
Modeling Genomic Diversity and Tumor Dependency in Malignant Melanoma
resolves10.1126/scitranslmed.3001451
Frequent and Focal
<i>FGFR1</i>
Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer
resolves10.1111/his.12115
Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma
resolves10.1073/pnas.0507200102
Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas
resolves10.1101/gad.14.9.1156
CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex
resolves10.1126/science.8016643
Regulation of MHC Class II Expression by Interferon-γ Mediated by the Transactivator Gene CIITA
resolves10.4049/jimmunol.176.7.4323
<i>Mycobacterium tuberculosis</i> 19-kDa Lipoprotein Inhibits IFN-γ-Induced Chromatin Remodeling of <i>MHC2TA</i> by TLR2 and MAPK Signaling
resolves10.1158/1078-0432.CCR-10-3283
Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes
resolves10.1158/2326-6066.CIR-21-0147
Context-Dependent Immunomodulatory Effects of MEK Inhibition Are Enhanced with T-cell Agonist Therapy
resolves10.1158/2326-6066.CIR-20-0235
Pharmacologic Inhibition of FGFR Modulates the Metastatic Immune Microenvironment and Promotes Response to Immune Checkpoint Blockade
resolves10.1158/2326-6066.CIR-18-0595
The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity
resolves10.1038/s41467-019-10873-y
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling
resolves10.1038/s41467-020-17914-x
FGF2 alters macrophage polarization, tumour immunity and growth and can be targeted during radiotherapy
resolves10.1016/j.cell.2018.08.048
Evolutionary Pressure against MHC Class II Binding Cancer Mutations
resolves10.1158/0008-5472.CAN-16-1219
Adoptive Transfer of Tumor-Specific Th2 Cells Eradicates Tumors by Triggering an
<i>In Situ</i>
Inflammatory Immune Response
resolves10.1038/s41586-019-1671-8
MHC-II neoantigens shape tumour immunity and response to immunotherapy
resolves10.1080/2162402X.2018.1560919
Cancer vaccines: designing artificial synthetic long peptides to improve presentation of class I and class II T cell epitopes by dendritic cells
resolves10.1007/s10120-020-01088-y
Resistance to FGFR1-targeted therapy leads to autophagy via TAK1/AMPK activation in gastric cancer
resolves10.1158/2159-8290.CD-21-0697
Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring
<i>FGF</i>
/
<i>FGFR</i>
Aberrations: A Phase I Dose-Expansion Study
The 1 reference without a DOI — listed, not checked
no DOI — not checkedKobayashi H, Wood M, Song Y, Appella E, Celis E. Defining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen. Cancer Res. 2000 Sep 15;60(18):5228–5236. PubMed PMID: 11016652.
What this badge says. CiteStamped means the CHECKABLE references of this
work were clean at the dated check: each resolved to a known work in a public registry, and none
carried a retraction notice at that time. It says nothing about the quality, findings,
or importance of the work itself, and nothing about references deposited without a DOI.
checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record
Embed this badge
Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.
<a href="https://citestamp.com/citestamped/10.1080/2162402x.2021.2021619"><img src="https://citestamp.com/citestamped/10.1080/2162402x.2021.2021619/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[](https://citestamp.com/citestamped/10.1080/2162402x.2021.2021619)